Febuxostat Impurity 23

HPTLC and Spectrophotometric Estimation of Febuxostat and Diclofenac Potassium in Their Combined Tablets
Fawzi A. El-Yazbi, Omayma A. Amin, Eman I. El-Kimary, Essam F. Khamis, Sameh E. Younis
Journal of Chromatographic Science, Volume 54, Issue 7, 1 August 2016, Pages 1146–1152
 
Study of impurity carryover and impurity profile in Febuxostat drug substance by LC-MS/MS technique
Mustakhusen H. Kadivar a, Praveen Kumar Sinhaa, Dharmendra Kushwaha,∗, Pijush Janaa,∗, Hitesh Sharmaa, Atul Bapodra
Journal of Pharmaceutical and Biomedical Analysis 56 (2011) 749–757
 
Development and Validation of a Stability-Indicating RP-HPLC Method for the Determination of Febuxostat (a Xanthine Oxidase Inhibitor)
Mathrusri Annapurna Mukthinuthalapati, Sai Pavan Kumar Bandaru, Venkatesh Bukkapatnam, Chitaranjan Mohapatro
Journal of Chromatographic Science, Volume 51, Issue 10, November/December 2013, Pages 931–938
 
Simple and Rapid Micellar Electrokinetic Chromatography Method for Simultaneous Determination of Febuxostat and its Related Impurities
Miranda Sertić1  · Ana Mornar1  · Biljana Nigović
Chromatographia volume 83, pages993–1000(2020)

Febuxostat Impurity 23 is chemically 2-(3-(5-(Ethoxycarbonyl)-4-methylthiazol-2-yl)-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid. Febuxostat Impurity 23 is supplied with detailed characterization data compliant with regulatory guideline. Febuxostat Impurity 23 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Febuxostat.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.